Video
Dr. Hafron on PARP inhibitors in prostate cancer
Author(s):
“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.
Video Player is loading.
In a video interview conducted at the 2021 LUGPA annual meeting, Jason M. Hafron, MD, discussed how his practice is using PARP inhibitors for the treatment of prostate cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan.
Related Videos
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
Related Content
